Back to News & Events

CFB Selects Third BioEntrepreneur-In-Residence

The Center for Biotechnology at Stony Brook University has appointed Andreas Grill as the Center?s third BioEntrepreneur-In-Residence (B-EIR). Mr. Grill brings over twenty years of experience in the pharmaceutical industry to his appointment of B-EIR, having most recently served as the Executive Director of Forest Research Institute for Forest Laboratories, Inc.

Mr. Grill will conduct due diligence to identify a technology or technologies around which he may build a company. As part of the B-EIR program, Mr. Grill will have access to the Center?s business and technology development support staff. Mr. Grill?s diverse and extensive experience in both business and research and development provide him with a unique perspective and advantage when it comes to launching a therapeutic-focused start-up. Read the full press release here.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 3083 [post_author] => 3 [post_date] => 2018-11-16 14:26:57 [post_date_gmt] => 2018-11-16 14:26:57 [post_content] => Update courtesy of BBC Entrepreneurial Training and Consulting NIH is strongly encouraging small businesses to contact the appropriate Institute or Center early in their application planning to ensure their technology is a priority for the Institute/Center. An updated SBIR/STTR Application Guide with additional instructions for SBIR Direct Phase II application preparation and submission will be posted by November 26, 2018. The following sections of each FOA are changed: Part 2, Section I. Funding Opportunity Description The following has been added at the end of the section for each FOA: PA-18-573 The following Components will not accept an SBIR Direct-to-Phase II submission: - National Institute of Nursing Research (NINR) - National Center for Complementary and Integrative Health (NCCIH) PA-18-574 The following Components will not accept an SBIR Direct-to-Phase II submission: - National Institute of Environmental Health Sciences (NIEHS ) - National Institute of Nursing Research (NINR) - National Center for Complementary and Integrative Health (NCCIH) - Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP) - Centers for Disease Control and Prevention (CDC) (All Components of CDC) - U.S. Food and Drug Administration (FDA) (All Components of FDA) Part 2, Section II. Award Information for both PA-18-573 and PA-18-574. Application types now allowed are: - New (Phase I, Fast-Track) - New (Direct Phase II) - Renewal (Phase II) - Resubmission (all phases) - Phase IIB Competing Renewal (Phase IIB) - Revision The OER Glossary and the SF424 (R&R) SBIR/STTR Application Guide provide details on these application types. [post_title] => Important SBIR/STTR Information Update from NIH [post_excerpt] => An updated SBIR/STTR Application Guide with additional instructions for SBIR Direct Phase II application preparation and submission will be posted by November 26, 2018. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => important-sbirsttr-information-update-from-nih [to_ping] => [pinged] => [post_modified] => 2018-11-16 14:26:57 [post_modified_gmt] => 2018-11-16 14:26:57 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=3083 [menu_order] => 110 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3578 [post_author] => 3 [post_date] => 2020-07-13 19:27:59 [post_date_gmt] => 2020-07-13 19:27:59 [post_content] => The Life Sciences Summit™ 2020 has gone digital! Join us online on November 17th & 18th as we spotlight the next wave of emerging companies. Our online event will continue to connect emerging biotech companies and academic innovators with the capital and strategic partners needed to move new discoveries into clinical development. Save the date and visit lifesciencessummit.org for updates If your organization is interested in presenting at the Summit, or if you would like sponsor the event, please contact Diane Fabel (diane.fabel@stonybrook.edu) or call 631.632.8521.     [post_title] => Attend the Life Sciences Summit Virtually in November! [post_excerpt] => Join us online on November 17th & 18, 2020 for the The Life Sciences Summit™! [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => join-us-at-lss-virtually-in-november [to_ping] => [pinged] => [post_modified] => 2020-09-14 14:22:27 [post_modified_gmt] => 2020-09-14 14:22:27 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3578 [menu_order] => 61 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 2210 [post_author] => 3 [post_date] => 2016-05-12 19:03:22 [post_date_gmt] => 2016-05-12 19:03:22 [post_content] => TheraSource LLC, a Feinstein Institute for Medical Research spin-out, has received a $3 million three-year Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH). The grant will support the development of human ghrelin as an innovative treatment to alleviate health damage caused by unintentional radiation exposure. TheraSource has been a client of the Center for Biotechnology and the organization is proud to have played an integral role in the helping the company advance their business and technology strategy. As noted by Diane Fabel, Director of Operations for the Center for Biotechnology, “The Phase II award for TheraSource is a significant landmark for the company and an important milestone for the region.” Ping Wang, MD, founder of TheraSource and Chief of Scientific Officer (CSO) of the Feinstein Institute has stated “Human ghrelin has been investigated in clinical trials of other indications.  With our new findings, we will soon be able to file an Investigational New Drug application to US Food and Drug Administration,” said Dr. Wang. “TheraSource has received investments to fund its various projects and is seeking strategic partnerships towards the goal of clinical development and commercialization.” For more details, read the company’s press release here. [post_title] => TheraSource LLC receives $3M SBIR Grant [post_excerpt] => TheraSource LLC, a Feinstein Institute for Medical Research spin-out, has received a $3 million three-year Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH). [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => therasource-llc-receives-3m-sbir-grant [to_ping] => [pinged] => [post_modified] => 2016-05-12 19:13:45 [post_modified_gmt] => 2016-05-12 19:13:45 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2210 [menu_order] => 181 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 260 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

Important SBIR/STTR Information Update from NIH

More Information

Attend the Life Sciences Summit Virtually in November!

More Information

TheraSource LLC receives $3M SBIR Grant

More Information